ReviewDiscover oncology2025
Advancing liver cancer diagnosis and treatment with multi-omics approaches: a systematic review.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Non-Invasive Assessment of Microvascular Invasion Risk in Hepatocellular Carcinoma Using Liquid Biopsy: Translational Insights and Clinical Implications.Diagnostics (Basel, Switzerland) · 2026Review
- Artificial intelligence driven exposome and multi omics integration for biomarker discovery in liver cancer: a literature review.Frontiers in immunology · 2026Review
- CENPA as a Genome Stability-Associated Biomarker in Hepatocellular Carcinoma: Multiomics Analysis and Experimental Validation.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), the most prevalent form of liver cancer, remains a major global health concern due to challenges in early detection and limited treatment options. Multi-omics technologies-such as genomics, proteomics, and metabolomics-enable comprehensive insights into the disease's molecular complexity. This systematic review explores how these approaches contribute to biomarker discovery, molecular classification, and personalized treatment in HCC research.
methodsWe conducted a structured review of 32 eligible studies, categorizing their computational methodologies into five primary analytical frameworks: survival analysis, unsupervised clustering, supervised machine learning, differential expression analysis, and pathway/network analysis. Notably, unsupervised clustering and supervised machine learning approaches, such as support vector machines, random forests, and deep learning models, were frequently used for subtype classification, feature selection, and predictive modeling.
resultsThe review identified that multi-omics approaches are widely used to discover biomarkers, classify HCC subtypes, and predict treatment responses. Common methods include clustering and machine learning. However, clinical validation remains limited, highlighting a gap in translational applicability.
conclusionFrom a clinical perspective, multi-omics integration coupled with machine learning holds immense potential for improving early diagnosis, patient stratification, and therapeutic targeting. However, challenges related to data integration, interpretability, and cohort diversity must be addressed to realize this potential. This review underscores the transformative role of machine learning-enhanced multi-omics in reshaping liver cancer diagnosis and treatment and outlines future directions to bridge the gap between computational advances and clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.